Literature DB >> 28527132

Gankyrin as a potential therapeutic target for cancer.

Chongchong Wang1, Li Cheng2.   

Abstract

Gankyrin is an oncoprotein that plays a central role in the development of cancer. Although researchers have increasingly focused on the relationships of gankyrin with carcinogenesis, metastasis and prognosis of different cancers, the molecular mechanisms are still unclear. In recent years, several interacting partners of gankyrin and cell signaling pathways regulated by gankyrin have been elucidated. In addition, accumulating evidence has indicated the contribution of microRNAs to regulating gankyrin expression in tumor cells. In this review, we summarize the major known roles of gankyrin in cancer cells and highlight the potential clinical relevance of targeting gankyrin. Graphical abstract ᅟ.

Entities:  

Keywords:  Gankyrin; Inhibitor; Protein–protein interaction; Signaling pathway; microRNAs

Mesh:

Substances:

Year:  2017        PMID: 28527132     DOI: 10.1007/s10637-017-0474-8

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  70 in total

1.  Structural basis for the recognition between the regulatory particles Nas6 and Rpt3 of the yeast 26S proteasome.

Authors:  Yoshihiro Nakamura; Takashi Umehara; Akiko Tanaka; Masami Horikoshi; Balasundaram Padmanabhan; Shigeyuki Yokoyama
Journal:  Biochem Biophys Res Commun       Date:  2007-05-29       Impact factor: 3.575

2.  Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells.

Authors:  Wen Sun; Jin Ding; Kun Wu; Bei-Fang Ning; Wen Wen; Han-Yong Sun; Tao Han; Lei Huang; Li-Wei Dong; Wen Yang; Xing Deng; Zhong Li; Meng-Chao Wu; Gen-Sheng Feng; Wei-Fen Xie; Hong-Yang Wang
Journal:  Hepatology       Date:  2011-10       Impact factor: 17.425

Review 3.  Hippo/Yap Signaling in Cardiac Development and Regeneration.

Authors:  Yang Xiao; John Leach; Jun Wang; James F Martin
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-06

Review 4.  Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.

Authors:  Satyanarayana Rachagani; Muzafar A Macha; Nicholas Heimann; Parthasarathy Seshacharyulu; Dhanya Haridas; Seema Chugh; Surinder K Batra
Journal:  Adv Drug Deliv Rev       Date:  2014-10-23       Impact factor: 15.470

Review 5.  Gankyrin: an intriguing name for a novel regulator of p53 and RB.

Authors:  Guillermina Lozano; Gerard P Zambetti
Journal:  Cancer Cell       Date:  2005-07       Impact factor: 31.743

6.  The oncoprotein, gankyrin, is up-regulated in middle ear cholesteatoma.

Authors:  Ki Hyun Kim; Hye Jin Lim; Yeon Ju Kim; Seung Won Kim; Young Sun Kim; Chunjie Tian; Keehyun Park; Tae Jun Park; Yun-Hoon Choung
Journal:  Acta Otolaryngol       Date:  2014-01-27       Impact factor: 1.494

7.  Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway.

Authors:  J Chen; M Bai; C Ning; B Xie; J Zhang; H Liao; J Xiong; X Tao; D Yan; X Xi; X Chen; Y Yu; R C Bast; Z Zhang; Y Feng; W Zheng
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

Review 8.  The PI3K/Akt Pathway in Tumors of Endocrine Tissues.

Authors:  Helen Louise Robbins; Angela Hague
Journal:  Front Endocrinol (Lausanne)       Date:  2016-01-11       Impact factor: 5.555

9.  Gankyrin has an antioxidative role through the feedback regulation of Nrf2 in hepatocellular carcinoma.

Authors:  Chun Yang; Ye-Xiong Tan; Guang-Zhen Yang; Jian Zhang; Yu-Fei Pan; Chen Liu; Jing Fu; Yao Chen; Zhi-Wen Ding; Li-Wei Dong; Hong-Yang Wang
Journal:  J Exp Med       Date:  2016-04-18       Impact factor: 14.307

Review 10.  C-Jun N-terminal kinase signalling pathway in response to cisplatin.

Authors:  Dong Yan; GuangYu An; Macus Tien Kuo
Journal:  J Cell Mol Med       Date:  2016-07-04       Impact factor: 5.310

View more
  6 in total

Review 1.  Small-Molecule Inhibitors of the Proteasome's Regulatory Particle.

Authors:  Christine S Muli; Wenzhi Tian; Darci J Trader
Journal:  Chembiochem       Date:  2019-05-24       Impact factor: 3.164

2.  Gankyrin Drives Malignant Transformation of Gastric Cancer and Alleviates Oxidative Stress via mTORC1 Activation.

Authors:  Bo Huang; Weiyang Cai; Qian Wang; Feng Liu; Ming Xu; Yanjie Zhang
Journal:  Oxid Med Cell Longev       Date:  2018-10-21       Impact factor: 6.543

3.  PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma.

Authors:  Leila Valanejad; Ashley Cast; Mary Wright; Karl-Dimiter Bissig; Rebekah Karns; Matthew T Weirauch; Nikolai Timchenko
Journal:  Commun Biol       Date:  2018-06-11

4.  Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines.

Authors:  Margaretha A Skowron; Günter Niegisch; Philipp Albrecht; Gommert van Koeveringe; Andrea Romano; Peter Albers; Wolfgang A Schulz; Michèle J Hoffmann
Journal:  Int J Mol Sci       Date:  2017-08-02       Impact factor: 5.923

5.  Gankyrin Promotes Tumor-Suppressor Protein Degradation to Drive Hepatocyte Proliferation.

Authors:  Amber M D'Souza; Yanjun Jiang; Ashley Cast; Leila Valanejad; Mary Wright; Kyle Lewis; Meenasri Kumbaji; Sheeniza Shah; David Smithrud; Rebekah Karns; Soona Shin; Nikolai Timchenko
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-05-24

6.  LMX1B-associated gankyrin expression predicts poor prognosis in glioma patients.

Authors:  Xu Guo; Haozhe Piao; Yixue Xue; Yunhui Liu; Hongyu Zhao
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.